country

Change Language

EN - English
FR - Français
DE - Deutsch
ES - Español
JA - 日本語
KO - 한국어

Country or Region:

United States

Product Name	Size / Unit Price	Qty

Total: USD 0.00 Checkout

Art. -Nr.: HY-136893

Copy Link Print Information

SP-6-27

SP-6-27 is a tubulin depolymerizing agent that binds to the colchicine site of β-tubulin. SP-6-27 induces G₂/M cell cycle arrest in ovarian cancer cells. SP-6-27 enhances intrinsic apoptosis in ovarian cancer cells through upregulation of Bax, Apaf-1, caspase-6, caspase-9, and caspase-3. SP-6-27 reduces ovarian cancer cell migration. SP-6-27 inhibits capillary tube formation by human umbilical vein endothelial cells. SP-6-27 shows minimum cytotoxicity to normal ovarian epithelia. SP-6-27 shows enhanced cytotoxicity in chemo-sensitive/resistant ovarian cancer cells when combined with Cisplatin (HY-17394). SP-6-27 can be used for the research of ovarian cancer.

Nur für Forschungszwecke. Wir verkaufen nicht an Patienten.

CAS. Nr.: 1384170-58-4
Formel: C₂₄H₂₄N₄O
Molecular Weight:384.48

Speicherung:

Please store the product under the recommended conditions in the Certificate of Analysis.

Data Sheet (279 KB)

SP-6-27 Chemical Structure

CAS. Nr.: 1384170-58-4

Größe

Preis

Verfügbarkeit

Menge

Amount: USD 0.00

* Bitte wählen Sie Menge, bevor Sie Artikel hinzufügen.

Top Publications Citing

Use of MCE Products

Fluorescent Dye

Strong Fluorescence Signal / Multi-Disciplinary Applications / High Fluorescence Specificity

Biologische Aktivität
- Beschreibung
- IC₅₀ & Target
- Cellular Effect
- In Vitro
Chemical Information
Reinheit & Dokumentation
Verweise
Calculators
Help & FAQs
Classifications
Bioz

Biologische Aktivität

Beschreibung

IC₅₀ & Target

Bax

Caspase 3

Caspase-6

Caspase-9

Alle Caspase Isoform-spezifische Produkte anzeigen :

Alle Bcl-2 Family Isoform-spezifische Produkte anzeigen :

Cellular Effect

Cell Line	Type	Value	Description	References
A 172	IC₅₀	7.4 nM Compound: 4e	Antiproliferative activity against human A172 cells after 5 days by MTT assay Antiproliferative activity against human A172 cells after 5 days by MTT assay	[PMID: 22608389]
A-375	IC₅₀	0.08 μM Compound: 4e	Antiproliferative activity against human A375 cells after 48 hrs by SRB assay Antiproliferative activity against human A375 cells after 48 hrs by SRB assay	[PMID: 22608389]
Astrocyte	IC₅₀	2033 nM Compound: 4e	Cytotoxicity against mouse primary astrocytes after 5 days by MTT assay Cytotoxicity against mouse primary astrocytes after 5 days by MTT assay	[PMID: 22608389]
LN-18	IC₅₀	13.3 nM Compound: 4e	Antiproliferative activity against human LN18 cells after 5 days by MTT assay Antiproliferative activity against human LN18 cells after 5 days by MTT assay	[PMID: 22608389]
LNCaP	IC₅₀	0.14 μM Compound: 4e	Antiproliferative activity against human LNCAP cells after 96 hrs by SRB assay Antiproliferative activity against human LNCAP cells after 96 hrs by SRB assay	[PMID: 22608389]
PC-3	IC₅₀	0.22 μM Compound: 4e	Antiproliferative activity against human PC3 cells after 96 hrs by SRB assay Antiproliferative activity against human PC3 cells after 96 hrs by SRB assay	[PMID: 22608389]
T98G	IC₅₀	12.5 nM Compound: 4e	Antiproliferative activity against human T98G cells after 5 days by MTT assay Antiproliferative activity against human T98G cells after 5 days by MTT assay	[PMID: 22608389]
U-87MG ATCC	IC₅₀	20.6 nM Compound: 4e	Antiproliferative activity against human U87 cells after 5 days by MTT assay Antiproliferative activity against human U87 cells after 5 days by MTT assay	[PMID: 22608389]
WM164	IC₅₀	0.16 μM Compound: 4e	Antiproliferative activity against human WM164 cells after 48 hrs by SRB assay Antiproliferative activity against human WM164 cells after 48 hrs by SRB assay	[PMID: 22608389]

In Vitro

SP-6-27 (0.001-10 μM; 72 h) potently inhibits proliferation in Cisplatin-sensitive and resistant ovarian cancer cells and exhibits minimal cytotoxicity to normal HOSEpiC cells (IC₅₀ = 0.10-0.84 μM for OVCA cells, 83.35 μM for HOSEpiC cells)^[1].
SP-6-27 (0.5 μM; 24 h) disrupts alpha-tubulin and beta-tubulin cytoskeletal structure, reducing microtubule density in ovarian cancer cells^[1].
SP-6-27 (0.5 μM; 48 h) reduces migration in ovarian cancer cells (A2780)^[1].
SP-6-27 (0.5 μM; 24 h) induces G₂-M cell cycle arrest in Cisplatin-sensitive and resistant ovarian cancer cells^[1].
SP-6-27 (0.5 μM; 24-48 h) induces apoptosis in Cisplatin-sensitive and resistant ovarian cancer cells^[1].
SP-6-27 upregulates pro-apoptotic genes (Bax, PAF-1, caspase-9, caspase-6, Caspase-3) and GADD45A in ovarian cancer cells^[1].
SP-6-27 (0.5 μM; 24-48 h) enhances cytotoxicity in Cisplatin-sensitive cells when treated simultaneously with Cisplatin and in Cisplatin-resistant cells when treated sequentially^[1].
SP-6-27 (0.5-1 μM; 24 h) inhibits capillary tube formation by HUVECs, even in the presence of tumor conditioned media^[1].

MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.

Cell Viability Assay^[1]

Cell Line:

cisplatin-sensitive OVCA (A2780, SKOV-3, TOV-112D), cisplatin-resistant OVCA (OVCAR-3, cis-A2780, cis-TOV-112D), HOSEpiC
Concentration:

0.001-10 μM
Incubation Time:

72 h
Result:

Exhibited potent cytotoxicity against Cisplatin-sensitive OVCA cells with a mean IC₅₀ of 0.14 μM and against cisplatin-resistant OVCA cells with a mean IC₅₀ of 0.36 μM; showed minimal cytotoxicity with an IC₅₀ of 83.35 μM in normal HOSEpiC cells.

Cell Migration Assay ^[1]

Cell Line:

A2780 OVCA cells
Concentration:

0.5 μM
Incubation Time:

48 h
Result:

Reduced migration compared to control cells when monitored over 48 h.

Cell Cycle Analysis^[1]

Cell Line:

Cisplatin-sensitive A2780 and Cisplatin-resistant cis-A2780 OVCA cells
Concentration:

0.5 μM
Incubation Time:

24 h
Result:

Caused a complete collapse of cells in G1 phase and a substantial increase in G2-M phase cells: 87.8% of A2780 cells were arrested in G2-M phase (vs. 16.40% in control) and 58.9% of cis-A2780 cells were arrested in G2-M phase (vs. 14.5% in control).

Apoptosis Analysis^[1]

Cell Line:

Cisplatin-sensitive A2780 and Cisplatin-resistant cis-A2780 OVCA cells
Concentration:

0.5 μM
Incubation Time:

24 h (caspase-3 microscopy); 24, 48 h (Annexin V/7-AAD)
Result:

Caused a pronounced increase in Annexin-V positive cells (early/late apoptotic) in both cell types at 24 and 48 h; showed increased cleaved caspase-3 activity in A2780 cells compared to control cells.

Chemical Information

CAS. Nr. 1384170-58-4
Molecular Weight 384.48
Formel C₂₄H₂₄N₄O
SMILES

N#CC1=C(OC2=CC(=CC=C2C1C=3C=CC(=C4C=CC=CC43)N(C)C)N(C)C)N
Versand

Room temperature in continental US; may vary elsewhere.
Speicherung

Please store the product under the recommended conditions in the Certificate of Analysis.

Reinheit & Dokumentation

Select Batch:

Reinheit: 99.98%

Assay: 99.98%

ee.: 99.98%

Data Sheet (279 KB)
COA (2659 KB)
Elemental Analysis Report (2659 KB)
HNMR (2659 KB)
CNMR (2659 KB)
RP-HPLC (2659 KB)
NP-HPLC (2659 KB)
MS (2659 KB)
LCMS (2659 KB)
IR (2659 KB)
GC (2659 KB)
OR (2659 KB)
SDS-PAGE (2659 KB)
SEC-HPLC (2659 KB)
Other Report (2659 KB)
Handling Instructions (2659 KB)

Verweise

[1]. Kulshrestha A, et al. Microtubule inhibitor, SP-6-27 inhibits angiogenesis and induces apoptosis in ovarian cancer cells. Oncotarget. 2017;8(40):67017-67028. Published 2017 May 2. [Content Brief]

Calculators

Molaritätsrechner

Mass (g) = Concentration (mol/L) × Volume (L) × Molecular Weight (g/mol)

Mass Mass

Konzentration Konzentration

Volumen Volumen

Molecular Weight Molecular Weight

Verdünnungsrechner

Konzentration _{(Stammlösung)} × Volumen _{(Stammlösung)} = Konzentration _{(Ziellösung)} × Volumen _{(Ziellösung)}

Konzentration _{(Stammlösung)} Konzentration _{(Stammlösung)}

Volumen _{(Stammlösung)} Volumen _{(Stammlösung)}

Konzentration _{(Ziellösung)} Konzentration _{(Ziellösung)}

Volumen _{(Ziellösung)} Volumen _{(Ziellösung)}

Help & FAQs

How should lyophilized recombinant proteins be reconstituted and stored?

1. Before opening the cap, centrifuge the vial at 13000 rpm for 20-30 seconds. This step will ensure that any lyophilized powder that may have adhered to the cap or walls is collected at the bottom of the vial, minimizing the risk of product loss.

MOQ

Minimum order quantity

100 mg

Angebot einholen Auf Lager

Other size

Angebot einholen

Amount: USD 0.00

Biologische Aktivität
- Beschreibung
- IC₅₀ & Target
- In Vitro
Chemical Information
Reinheit & Dokumentation
Verweise

Produktname:
Art. -Nr.:
Menge:
MCE Japan Authorized Agent:

Produktname:
CAS. Nr.:
Species:
Reinheit:
Menge:

SP-6-27

Alle Caspase Isoform-spezifische Produkte anzeigen

Alle Bcl-2 Family Isoform-spezifische Produkte anzeigen

Biologische Aktivität

Chemical Information

Reinheit & Dokumentation

Verweise

Calculators

Help & FAQs

SP-6-27 Related Classifications

HY-136893 Related Classifications